NASDAQ:ABCM
Delisted
Abcam plc Stock News
$23.99
+0 (+0%)
At Close: Mar 04, 2024
Danaher completes $5.7 billion acquisition of Abcam
08:14am, Wednesday, 06'th Dec 2023
Medical tools supplier Danaher said on Wednesday it has completed the $5.7 billion acquisition of Abcam , overcoming the initial opposition from the founder of the protein consumables maker.
Exlusive: Why Abcam founder believes Danaher's acquisition offer falls short
08:46am, Monday, 16'th Oct 2023
In an exclusive interview with Thomas Warner (TW) of Proactive London, Dr Jonathan Milner (JM), the founder of life sciences company Abcam PLC (NASDAQ:ABCM), discusses why he believes the $24 per shar
GMED or ABCM: Which Is the Better Value Stock Right Now?
12:47pm, Thursday, 05'th Oct 2023
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Abcam PLC Sponsored ADR (ABCM). But which of these two stocks offers value inves
Danaher Buys Abcam for $5.7 Billion to Expand Its Product Offerings
04:55pm, Monday, 28'th Aug 2023
Medical tool supplier Danaher (DHR) is expanding its product offerings by purchasing British biotech firm Abcam Plc (ABCM) for $5.7 billion, including debt.
Danaher acquires biotech supplier Abcam for $5.7B
09:32am, Monday, 28'th Aug 2023
Danaher (NYSE:DHR) said it will be acquiring UK-based biotechnology supplier Abcam (AIM:ABC) for $24 per share or a total enterprise value of about $5.7 billion. Danaher (NYSE:DHR) beat out rivals who
Medical tech firm Danaher to buy Abcam in deal valued at $5.7 bln
08:33am, Monday, 28'th Aug 2023
Danaher Corp said on Monday it would buy smaller rival Abcam Plc in a deal valued at $5.7 billion including debt, as the medical tools supplier eyes bigger contracts by expanding its services.
Danaher to Buy Abcam in $5.7 Billion Deal. Investors Don't Like the Premium.
08:32am, Monday, 28'th Aug 2023
The industrial scientific-supplies company agrees to acquire all shares outstanding for $24.00 each.
Abcam agrees to be acquired by Danaher in $5.7B deal
07:54am, Monday, 28'th Aug 2023
Abcam Plc stock ABCM, +3.87% was up 0.4% in premarket trades Monday after it said it agreed to be acquired by Danaher Corp. DHR, +0.78% for $24 a share in cash in a deal that values the maker of antib
Exclusive: Danaher in the lead to acquire biomedical equipment vendor Abcam-sources
02:04pm, Friday, 25'th Aug 2023
Danaher Corp is in the lead to acquire Abcam Plc , a provider of supplies to life science researchers with a market value of $5.1 billion, as it expands its biomedical offerings, people familiar with
Why Shares of Abcam Are Jumping Friday
03:44pm, Friday, 23'rd Jun 2023
Abcam specializes in products, such as assays or reagents, used in biologic drug discovery. The company saw revenue grow but reported a loss in 2022.
Are You Looking for a Top Momentum Pick? Why Abcam PLC Sponsored ADR (ABCM) is a Great Choice
01:19pm, Wednesday, 21'st Jun 2023
Does Abcam PLC Sponsored ADR (ABCM) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 Stocks With Upgraded Broker Ratings for Robust Returns
08:48am, Wednesday, 21'st Jun 2023
As brokers have a deeper insight into stocks, one must follow rating upgrades for solid returns. We choose Abcam (ABCM), Maxeon Solar (MAXN) and Allegiant Travel (ALGT) as these witness rating upgrade
Is Abcam (ABCM) Outperforming Other Medical Stocks This Year?
11:01am, Tuesday, 20'th Jun 2023
Here is how Abcam PLC Sponsored ADR (ABCM) and Apyx Medical (APYX) have performed compared to their sector so far this year.
Why Shares in Abcam Surged This Week
12:47pm, Thursday, 15'th Jun 2023
Abcam operates in some highly attractive end markets, but its operational execution is not what it should be, according to its funder and former director. Dr. Jonathan Milner has called for the remova
Abcam: Nosebleed Valuations, Flat Growth Profile Justify Hold Rating
09:00am, Friday, 09'th Jun 2023
Abcam plc's outlook remains unchanged after a mixed FY'22, with improvements needed in fundamental, sentiment, and valuation factors to attract buyers. Despite a strong FY'22, ABCM's poor returns on c